PDI Inc (Nasdaq: PDII) said it has signed a definitive agreement to sell its commercial services business (CSO) to Publicis Healthcare Communications Group, part of Publicis Groupe (Euronext Paris: FR0000130577) for an initial $33 million.
About $7 million of the initial amount will be contingent upon securing certain CSO client commitments, plus an earnout payment based on 2016 CSO revenue.
Nancy Lurker, chief executive of PDI, said: “Our board of directors believes that this transaction is in the best interest of our clients, our employees, and our stockholders. Our agreement with Publicis Healthcare Communications Group is a win-win situation for both companies and maximizes the value of our CSO business for our stockholders.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze